Encouraging Phase 1b results for anti-IL-15 antibody TEV-'408 in vitiligo showed significant facial and total body repigmentation, with a favorable safety profile. Advancement to Phase 2b is planned, addressing a major unmet need for systemic therapies.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.